|
KMID : 1144320230550010099
|
|
감염과 화학요법
2023 Volume.55 No. 1 p.99 ~ p.104
|
|
|
Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
|
|
Lim Hee-Ji
Jang Sun-Dong
In Hyun-Ju
Kim Kwang-Wook
Choi Eun-Bee
Kim Soo-Ji
Lim Hye-Jung
Yim Min-Su
Ouh In-Ohk
Kim Byung-Chul
Do Hyeon-Nam
Lee June-Woo
Kim Byoung-Guk
Lee Yoo-kyoung
|
|
|
Abstract
|
|
|
|
The immunogenicity of a heterologous vaccination regimen consisting of ChAdOx1 nCoV-19 (a chimpanzee adenovirus-vectored vaccine) followed by mRNA-1273 (a lipid?nanoparticle-encapsulated mRNA-based vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the omicron variant (B.1.1.529), is poorly studied. The aim of this study was to evaluate the neutralizing antibody activity and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA-1273 prime-boost vaccination against wild-type (BetaCoV/Korea/KCDC03/2020), alpha, beta, gamma, delta, and omicron variants of SARS-CoV-2 in Korea. A 50% neutralizing dilution (ND50) titer was determined in serum samples using the plaque reduction neutralization test. Antibody titer decreased significantly at 3 months compared with that at 2 weeks after the 2nd dose. On comparing the ND50 titers for the above-mentioned variants of concerns, it was observed that the ND50 titer for the omicron variant was the lowest. This study provides insights into cross-vaccination effects and can be useful for further vaccination strategies in Korea.
|
|
|
KEYWORD
|
|
|
COVID-19 vaccine, Heterologous vaccination, Immunity, Omicron variant, Korea
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|